Interleukin‐10 mRNA expression in B‐cell chronic lymphocytic leukaemia inversely correlates with progression of disease

Abstract

Interleukin-10 (IL-10) has been shown in vitro to inhibit survival and spontaneous DNA synthesis in B-cell chronic lymphocytic leukaemia (B-CELL) cells by induction of programmed cell death. We have analysed the presence of mRNA transcripts for IL-10 in purified B-CLL cells from 35 patients by RT-PCR. Transcripts for IL-10 were detected in 11/20 patients with non-progressive disease. In cell preparations from patients with progressive B-CLL IL-10 mRNA were detected in only 2/15 samples (P < or = 0.01). The Epstein-Barr virus status of the cells did not account for the difference in IL-10 mRNA expression observed between the two groups of patients. Thus, IL-10 mRNA expression in leukaemic cells from patients with B-CLL was strongly associated with non-progressive disease. This finding may support other observations suggesting that IL-10 might be a candidate for immune therapy of progressive B-CLL.

Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL.

“…Many of these lymphomas have been shown to be comprised of CD5ϩ B cells (24,25). We as well as others have reported that IL-10 mRNA levels can also be varied in CLL (6,8,26). However, the NZB mouse, the murine model of CLL, has consistently elevated serum IL-10 levels and increased IL-10 mRNA expression in the malignant B-1 cells.…”

ALeishmaniaHomologue of Receptors for Activated C‐Kinase (LACK) Induces Both Interferon‐γ and Interleukin‐10 in Natural Killer Cells of Healthy Blood Donors

“…Complementary DNA (cDNA) was prepared from the RNA using reverse transcriptase (RT) polymerase chain reaction (PCR) analysis. The total mRNA was assessed by performing a PCR analysis with the primers for b 2 -microglobulin [16], which is structurally expressed by all cells. The mRNA for a given cytokine in the individual cell type cDNA preparation was determined in the PCR using primers designed by Pisa et al for IFNg [17] and IL-12 (Pharmacia Biotech, Uppsala, Sweden) and IL-10 (Scandinavia Gene Synthesis, Kö ping, Sweden).…”

Interleukin-10 Therapy—Review of a New Approach

“…Lymphoma. Tumor cells from B, T, and NK cell lymphoma are able to produce biologically active IL-10 ( Kitabayashi et al, 1995;Masood et al, 1995;Sjoberg et al, 1996;Beatty et al, 1997;Boulland et al, 1998;Jones et al, 1999). As early as 1993, Favrot and coauthors (Blay et al, 1993) investigated IL-10 serum levels using an ELISA, which detects both viral and human IL-10 in patients with active non-Hodgkin's lymphoma (NHL) and healthy volunteers.…”